108 results about "Hemophilus parasuis" patented technology

The invention relates to the field of haemophilus parasuis vaccines in veterinary biological products, in particular to a haemophilus parasuis LC strain. The collection number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.5257. The invention also relates to application of the haemophilus parasuis LC strain to preparation of haemophilus parasuis inactivated vaccines. The haemophilus parasuis LC strain has stronger pathogenicity to pigs and has better immunogenicity; an inactivated alumina gel vaccine prepared by the strain is safe and reliable; not only a homologous attacking protection is provided, but also a better cross protection to blood serums type 4, type 5, type 10, type 12, type 14 and type 15 HPS (Hantavirus Pulmonary Syndrome) heterologous attacking can be provided; after the pigs are immunized, a stronger immunity can be generated and the morbidity and the mortality of the inoculated pigs are obviously reduced; the immune effect achieves or is better than the traditional commercialized vaccines in the market; the vaccine has the advantages to compete with like products at home and abroad and is capable of effectively preventing the epidemic and the transmission of a haemophilus parasuis disease and reducing the economic losses caused by the disease, so that the application range is wide.

The invention discloses an indirect ELISA (enzyme-linked immuno sorbent assay) kit for detecting a haemophilus parasuis antibody. The kit consists of an ELISA coating plate with haemophilus parasuis cytolethal distending toxin)-C protein serving as a coating antigen, a to-be-detected sample dilution plate, a positive contrast serum, a negative contrast serum, 20-time concentrated washing liquid, a serum sample dilution solution, an enzyme-labeled antibody working solution, a developing solution and a terminating solution. A judgment standard is that if an S / P value is less than 0.200, a sample to be detected is negative; if the S / P value is greater than or equal to 0.200, the to-be-detected sample is positive; the S / P value is obtained according to a formula: S / P value=(the mean value of the to-be-detected sample OD450nm-the mean value of a negative contrast OD450nm) / (the mean value of a positive sample OD450nm-the mean value of the negative contrast OD450nm). Due to the specificity test, the sensitivity test, the repetitiveness test, the coincidence rate test, the test for comparing the kit disclosed by the invention with a kit on sale, the clinical application test and the like, the kit disclosed by the invention has the characteristics of high specificity, high sensitivity, high repetitiveness and the like and is high in coincidence rate to the same type of products on sale home and abroad; the indirect ELISA kit can be used for clinical large-scale detection and epidemiological investigation for the haemophilus parasuis antibodies.

The invention discloses application of a haemophilus parasuis CdtB hybridoma cell and a monoclonal antibody, and belongs to the field of detection, diagnosis and treatment of animal infectious diseases. The preservation number of the haemophilus parasuis CdtB hybridoma cell is CCTCC NO:C201910, the subclass of the monoclonal antibody generated by the haemophilus parasuis CdtB hybridoma cell is IgG1, the light chain type is kappa, and the recognized epitope amino acid sequence is highly conservative in haemophilus parasuis. The monoclonal antibody disclosed by the invention is high in titer, can identify all serotype haemophilus parasuis, and also has neutralizing activity against CdtB. The monoclonal antibody and the epitope amino acid sequence recognized by the monoclonal antibody can bewidely applied to etiological diagnosis of haemophilus parasuis, serological diagnosis, immunological detection, disease prevention and treatment, wild virus infection and vaccine distinguishing and the like of haemophilus parasuis, and are used for preparing products related to the application.

The invention discloses a streptococcus suis disease-haemophilus parasuis disease-porcine infectious pleuropneumonia triple subunit vaccine and a preparation method thereof. The triple subunit vaccine contains streptococcus suis antigen proteins MRP, SLY and EF, haemophilus parasuis antigen proteins AfuA, OppA2, CdtB and OppA, and actinobacillus pleuropneumoniae antigen proteins ApxI, ApxII and OMP. Experiments prove that the vaccine can stimulate strong immune response of mice, and has a good cross protection effect on streptococcus suis, haemophilus parasuis and actinobacillus pleuropneumoniae challenge mice with different serotypes, which fully shows that the triple subunit vaccine prepared in the invention has a good protection effect. Therefore, the invention lays a solid foundation for developing an efficient, broad-spectrum and cheap streptococcus suis disease-haemophilus parasuis disease-porcine infectious pleuropneumonia vaccine, and provides an effective technical means for preventing and treating streptococcus suis disease, haemophilus parasuis disease and porcine infectious pleuropneumonia.

The invention belongs to the field of veterinary vaccines, particularly relates to a quad inactivated vaccine of PCV2-type baculovirus, swine mycoplasma hyopneumoniae, a porcine influenza virus and haemophilus parasuis and further discloses a preparation method for the quad inactivated vaccine and application of the quad inactivated vaccine. The quad inactivated vaccine disclosed by the inventioncontains inactivated protein Cap expressed by the PCV2-type baculovirus, inactivated swine mycoplasma hyopneumoniae, an inactivated porcine influenza virus H1N1subtype virus, inactivated haemophilus parasuis types 4, 5 and 13 and an adjuvant of the vaccine; four kinds of antigens are free of interference to one another, four kinds of protection can be achieved by one injection, and four kinds of epidemic diseases can be prevented through one-time immunization; and meanwhile, in view of toxic substance counteracting protection and serum antibody level, the immunization effect reaches or exceedsthat of each single commodity vaccine, the immunization duration is long, the efficacy is durable, and the quad inactivated vaccine has the advantages that the safety is good, the preparation methodis simple, the immunization is convenient, the immunization cost is reduced, and the like.